Measurements of transcallosally mediated cortical inhibition for differentiating parkinsonian syndromes.
Identifieur interne : 003411 ( PubMed/Checkpoint ); précédent : 003410; suivant : 003412Measurements of transcallosally mediated cortical inhibition for differentiating parkinsonian syndromes.
Auteurs : Alexander Wolters [Allemagne] ; Joseph Classen ; Erwin Kunesch ; Annette Grossmann ; Reiner BeneckeSource :
- Movement disorders : official journal of the Movement Disorder Society [ 0885-3185 ] ; 2004.
English descriptors
- KwdEn :
- Aged, Antiparkinson Agents (therapeutic use), Basal Ganglia Diseases (drug therapy), Basal Ganglia Diseases (pathology), Basal Ganglia Diseases (physiopathology), Corpus Callosum (pathology), Corpus Callosum (physiopathology), Diagnosis, Differential, Electromyography, Humans, Levodopa (therapeutic use), Magnetic Resonance Imaging, Magnetoencephalography (methods), Middle Aged, Motor Cortex (pathology), Motor Cortex (physiopathology), Multiple System Atrophy (drug therapy), Multiple System Atrophy (pathology), Multiple System Atrophy (physiopathology), Muscle, Skeletal (pathology), Muscle, Skeletal (physiopathology), Nerve Degeneration (drug therapy), Nerve Degeneration (pathology), Nerve Degeneration (physiopathology), Nerve Net (pathology), Nerve Net (physiopathology), Neural Inhibition (physiology), Parkinsonian Disorders (drug therapy), Parkinsonian Disorders (pathology), Parkinsonian Disorders (physiopathology), Supranuclear Palsy, Progressive (drug therapy), Supranuclear Palsy, Progressive (pathology), Supranuclear Palsy, Progressive (physiopathology).
- MESH :
- chemical , therapeutic use : Antiparkinson Agents, Levodopa.
- drug therapy : Basal Ganglia Diseases, Multiple System Atrophy, Nerve Degeneration, Parkinsonian Disorders, Supranuclear Palsy, Progressive.
- methods : Magnetoencephalography.
- pathology : Basal Ganglia Diseases, Corpus Callosum, Motor Cortex, Multiple System Atrophy, Muscle, Skeletal, Nerve Degeneration, Nerve Net, Parkinsonian Disorders, Supranuclear Palsy, Progressive.
- physiology : Neural Inhibition.
- physiopathology : Basal Ganglia Diseases, Corpus Callosum, Motor Cortex, Multiple System Atrophy, Muscle, Skeletal, Nerve Degeneration, Nerve Net, Parkinsonian Disorders, Supranuclear Palsy, Progressive.
- Aged, Diagnosis, Differential, Electromyography, Humans, Magnetic Resonance Imaging, Middle Aged.
Abstract
Clinicopathologic evidence suggests differential involvement of cortex and corpus callosum (CC) in various disorders presenting with a parkinsonian syndrome. We tested the hypothesis of whether neurophysiologic and morphometric assessments of CC as surrogate parameters of cortical involvement could be helpful in differential diagnosis of parkinsonian disorders. The integrity of CC was assessed neurophysiologically by measuring the ipsilateral silent period (iSP) evoked by transcranial magnetic stimulation (TMS) in a total of 25 patients with idiopathic parkinsonian syndromes (IPS), corticobasal ganglionic degeneration (CBD), progressive supranuclear palsy (PSP), or multiple system atrophy (MSA). Additionally, morphometric analyses of magnetic resonance imaging (MRI) measurements of CC was carried out in all patients. iSP was abnormal in all 5 CBD and all 5 PSP patients, whereas it was intact in all 10 IPS patients and all 5 MSA patients. Among various MRI parameters of CC, testing between different groups revealed a significant difference only for measurements of the middle part of the truncus. CBD and PSP patients exhibited a significant atrophy as compared with control subjects. These data suggest impairment of callosal integrity in patients with CBD and PSP. iSP measurements may be a useful clinical neurophysiologic test in differential diagnosis of patients with parkinsonian syndromes.
DOI: 10.1002/mds.20064
PubMed: 15133815
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
pubmed:15133815Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Measurements of transcallosally mediated cortical inhibition for differentiating parkinsonian syndromes.</title><author><name sortKey="Wolters, Alexander" sort="Wolters, Alexander" uniqKey="Wolters A" first="Alexander" last="Wolters">Alexander Wolters</name><affiliation wicri:level="1"><nlm:affiliation>Human Cortical Physiology Laboratory, Department of Neurology, University of Rostock, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Human Cortical Physiology Laboratory, Department of Neurology, University of Rostock</wicri:regionArea><wicri:noRegion>University of Rostock</wicri:noRegion><wicri:noRegion>University of Rostock</wicri:noRegion><wicri:noRegion>University of Rostock</wicri:noRegion></affiliation></author><author><name sortKey="Classen, Joseph" sort="Classen, Joseph" uniqKey="Classen J" first="Joseph" last="Classen">Joseph Classen</name></author><author><name sortKey="Kunesch, Erwin" sort="Kunesch, Erwin" uniqKey="Kunesch E" first="Erwin" last="Kunesch">Erwin Kunesch</name></author><author><name sortKey="Grossmann, Annette" sort="Grossmann, Annette" uniqKey="Grossmann A" first="Annette" last="Grossmann">Annette Grossmann</name></author><author><name sortKey="Benecke, Reiner" sort="Benecke, Reiner" uniqKey="Benecke R" first="Reiner" last="Benecke">Reiner Benecke</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2004">2004</date><idno type="RBID">pubmed:15133815</idno><idno type="pmid">15133815</idno><idno type="doi">10.1002/mds.20064</idno><idno type="wicri:Area/PubMed/Corpus">003472</idno><idno type="wicri:Area/PubMed/Curation">003472</idno><idno type="wicri:Area/PubMed/Checkpoint">003411</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Measurements of transcallosally mediated cortical inhibition for differentiating parkinsonian syndromes.</title><author><name sortKey="Wolters, Alexander" sort="Wolters, Alexander" uniqKey="Wolters A" first="Alexander" last="Wolters">Alexander Wolters</name><affiliation wicri:level="1"><nlm:affiliation>Human Cortical Physiology Laboratory, Department of Neurology, University of Rostock, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Human Cortical Physiology Laboratory, Department of Neurology, University of Rostock</wicri:regionArea><wicri:noRegion>University of Rostock</wicri:noRegion><wicri:noRegion>University of Rostock</wicri:noRegion><wicri:noRegion>University of Rostock</wicri:noRegion></affiliation></author><author><name sortKey="Classen, Joseph" sort="Classen, Joseph" uniqKey="Classen J" first="Joseph" last="Classen">Joseph Classen</name></author><author><name sortKey="Kunesch, Erwin" sort="Kunesch, Erwin" uniqKey="Kunesch E" first="Erwin" last="Kunesch">Erwin Kunesch</name></author><author><name sortKey="Grossmann, Annette" sort="Grossmann, Annette" uniqKey="Grossmann A" first="Annette" last="Grossmann">Annette Grossmann</name></author><author><name sortKey="Benecke, Reiner" sort="Benecke, Reiner" uniqKey="Benecke R" first="Reiner" last="Benecke">Reiner Benecke</name></author></analytic><series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title><idno type="ISSN">0885-3185</idno><imprint><date when="2004" type="published">2004</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term><term>Antiparkinson Agents (therapeutic use)</term><term>Basal Ganglia Diseases (drug therapy)</term><term>Basal Ganglia Diseases (pathology)</term><term>Basal Ganglia Diseases (physiopathology)</term><term>Corpus Callosum (pathology)</term><term>Corpus Callosum (physiopathology)</term><term>Diagnosis, Differential</term><term>Electromyography</term><term>Humans</term><term>Levodopa (therapeutic use)</term><term>Magnetic Resonance Imaging</term><term>Magnetoencephalography (methods)</term><term>Middle Aged</term><term>Motor Cortex (pathology)</term><term>Motor Cortex (physiopathology)</term><term>Multiple System Atrophy (drug therapy)</term><term>Multiple System Atrophy (pathology)</term><term>Multiple System Atrophy (physiopathology)</term><term>Muscle, Skeletal (pathology)</term><term>Muscle, Skeletal (physiopathology)</term><term>Nerve Degeneration (drug therapy)</term><term>Nerve Degeneration (pathology)</term><term>Nerve Degeneration (physiopathology)</term><term>Nerve Net (pathology)</term><term>Nerve Net (physiopathology)</term><term>Neural Inhibition (physiology)</term><term>Parkinsonian Disorders (drug therapy)</term><term>Parkinsonian Disorders (pathology)</term><term>Parkinsonian Disorders (physiopathology)</term><term>Supranuclear Palsy, Progressive (drug therapy)</term><term>Supranuclear Palsy, Progressive (pathology)</term><term>Supranuclear Palsy, Progressive (physiopathology)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiparkinson Agents</term><term>Levodopa</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Basal Ganglia Diseases</term><term>Multiple System Atrophy</term><term>Nerve Degeneration</term><term>Parkinsonian Disorders</term><term>Supranuclear Palsy, Progressive</term></keywords><keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Magnetoencephalography</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Basal Ganglia Diseases</term><term>Corpus Callosum</term><term>Motor Cortex</term><term>Multiple System Atrophy</term><term>Muscle, Skeletal</term><term>Nerve Degeneration</term><term>Nerve Net</term><term>Parkinsonian Disorders</term><term>Supranuclear Palsy, Progressive</term></keywords><keywords scheme="MESH" qualifier="physiology" xml:lang="en"><term>Neural Inhibition</term></keywords><keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Basal Ganglia Diseases</term><term>Corpus Callosum</term><term>Motor Cortex</term><term>Multiple System Atrophy</term><term>Muscle, Skeletal</term><term>Nerve Degeneration</term><term>Nerve Net</term><term>Parkinsonian Disorders</term><term>Supranuclear Palsy, Progressive</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Aged</term><term>Diagnosis, Differential</term><term>Electromyography</term><term>Humans</term><term>Magnetic Resonance Imaging</term><term>Middle Aged</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Clinicopathologic evidence suggests differential involvement of cortex and corpus callosum (CC) in various disorders presenting with a parkinsonian syndrome. We tested the hypothesis of whether neurophysiologic and morphometric assessments of CC as surrogate parameters of cortical involvement could be helpful in differential diagnosis of parkinsonian disorders. The integrity of CC was assessed neurophysiologically by measuring the ipsilateral silent period (iSP) evoked by transcranial magnetic stimulation (TMS) in a total of 25 patients with idiopathic parkinsonian syndromes (IPS), corticobasal ganglionic degeneration (CBD), progressive supranuclear palsy (PSP), or multiple system atrophy (MSA). Additionally, morphometric analyses of magnetic resonance imaging (MRI) measurements of CC was carried out in all patients. iSP was abnormal in all 5 CBD and all 5 PSP patients, whereas it was intact in all 10 IPS patients and all 5 MSA patients. Among various MRI parameters of CC, testing between different groups revealed a significant difference only for measurements of the middle part of the truncus. CBD and PSP patients exhibited a significant atrophy as compared with control subjects. These data suggest impairment of callosal integrity in patients with CBD and PSP. iSP measurements may be a useful clinical neurophysiologic test in differential diagnosis of patients with parkinsonian syndromes.</div></front></TEI><pubmed><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">15133815</PMID><DateCreated><Year>2004</Year><Month>05</Month><Day>10</Day></DateCreated><DateCompleted><Year>2004</Year><Month>09</Month><Day>21</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0885-3185</ISSN><JournalIssue CitedMedium="Print"><Volume>19</Volume><Issue>5</Issue><PubDate><Year>2004</Year><Month>May</Month></PubDate></JournalIssue><Title>Movement disorders : official journal of the Movement Disorder Society</Title><ISOAbbreviation>Mov. Disord.</ISOAbbreviation></Journal><ArticleTitle>Measurements of transcallosally mediated cortical inhibition for differentiating parkinsonian syndromes.</ArticleTitle><Pagination><MedlinePgn>518-28</MedlinePgn></Pagination><Abstract><AbstractText>Clinicopathologic evidence suggests differential involvement of cortex and corpus callosum (CC) in various disorders presenting with a parkinsonian syndrome. We tested the hypothesis of whether neurophysiologic and morphometric assessments of CC as surrogate parameters of cortical involvement could be helpful in differential diagnosis of parkinsonian disorders. The integrity of CC was assessed neurophysiologically by measuring the ipsilateral silent period (iSP) evoked by transcranial magnetic stimulation (TMS) in a total of 25 patients with idiopathic parkinsonian syndromes (IPS), corticobasal ganglionic degeneration (CBD), progressive supranuclear palsy (PSP), or multiple system atrophy (MSA). Additionally, morphometric analyses of magnetic resonance imaging (MRI) measurements of CC was carried out in all patients. iSP was abnormal in all 5 CBD and all 5 PSP patients, whereas it was intact in all 10 IPS patients and all 5 MSA patients. Among various MRI parameters of CC, testing between different groups revealed a significant difference only for measurements of the middle part of the truncus. CBD and PSP patients exhibited a significant atrophy as compared with control subjects. These data suggest impairment of callosal integrity in patients with CBD and PSP. iSP measurements may be a useful clinical neurophysiologic test in differential diagnosis of patients with parkinsonian syndromes.</AbstractText><CopyrightInformation>Copyright 2004 Movement Disorder Society</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wolters</LastName><ForeName>Alexander</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Human Cortical Physiology Laboratory, Department of Neurology, University of Rostock, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Classen</LastName><ForeName>Joseph</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Kunesch</LastName><ForeName>Erwin</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Grossmann</LastName><ForeName>Annette</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Benecke</LastName><ForeName>Reiner</ForeName><Initials>R</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Mov Disord</MedlineTA><NlmUniqueID>8610688</NlmUniqueID><ISSNLinking>0885-3185</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000978">Antiparkinson Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>46627O600J</RegistryNumber><NameOfSubstance UI="D007980">Levodopa</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000978">Antiparkinson Agents</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D001480">Basal Ganglia Diseases</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName><QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName><QualifierName MajorTopicYN="N" UI="Q000503">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D003337">Corpus Callosum</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000473">pathology</QualifierName><QualifierName MajorTopicYN="N" UI="Q000503">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D003937">Diagnosis, Differential</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D004576">Electromyography</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D007980">Levodopa</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008279">Magnetic Resonance Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015225">Magnetoencephalography</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000379">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D009044">Motor Cortex</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName><QualifierName MajorTopicYN="N" UI="Q000503">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D019578">Multiple System Atrophy</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName><QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName><QualifierName MajorTopicYN="N" UI="Q000503">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D018482">Muscle, Skeletal</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName><QualifierName MajorTopicYN="N" UI="Q000503">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D009410">Nerve Degeneration</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName><QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName><QualifierName MajorTopicYN="N" UI="Q000503">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D009415">Nerve Net</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName><QualifierName MajorTopicYN="N" UI="Q000503">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D009433">Neural Inhibition</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D020734">Parkinsonian Disorders</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000473">pathology</QualifierName><QualifierName MajorTopicYN="N" UI="Q000503">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D013494">Supranuclear Palsy, Progressive</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName><QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName><QualifierName MajorTopicYN="N" UI="Q000503">physiopathology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2004</Year><Month>5</Month><Day>11</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2004</Year><Month>9</Month><Day>24</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2004</Year><Month>5</Month><Day>11</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">15133815</ArticleId><ArticleId IdType="doi">10.1002/mds.20064</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Allemagne</li></country></list><tree><noCountry><name sortKey="Benecke, Reiner" sort="Benecke, Reiner" uniqKey="Benecke R" first="Reiner" last="Benecke">Reiner Benecke</name><name sortKey="Classen, Joseph" sort="Classen, Joseph" uniqKey="Classen J" first="Joseph" last="Classen">Joseph Classen</name><name sortKey="Grossmann, Annette" sort="Grossmann, Annette" uniqKey="Grossmann A" first="Annette" last="Grossmann">Annette Grossmann</name><name sortKey="Kunesch, Erwin" sort="Kunesch, Erwin" uniqKey="Kunesch E" first="Erwin" last="Kunesch">Erwin Kunesch</name></noCountry><country name="Allemagne"><noRegion><name sortKey="Wolters, Alexander" sort="Wolters, Alexander" uniqKey="Wolters A" first="Alexander" last="Wolters">Alexander Wolters</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PubMed/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003411 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 003411 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= PubMed
|étape= Checkpoint
|type= RBID
|clé= pubmed:15133815
|texte= Measurements of transcallosally mediated cortical inhibition for differentiating parkinsonian syndromes.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i -Sk "pubmed:15133815" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd \
| NlmPubMed2Wicri -a MovDisordV3
| This area was generated with Dilib version V0.6.23. |  |